Farxiga and Zolpidem Interaction: Safety, Risks, and Clinical Guidance
At a glance
- Drug identity / dapagliflozin is a brand-name (Farxiga) SGLT2 inhibitor used for type 2 diabetes, heart failure, and chronic kidney disease; zolpidem is a Schedule IV Z-drug hypnotic (brand name Ambien) used for short-term insomnia
- Pharmacokinetic overlap / dapagliflozin is cleared mainly by UGT1A9 glucuronidation; zolpidem is cleared mainly by CYP3A4; the two pathways do not meaningfully overlap
- Pharmacodynamic overlap / dapagliflozin-related volume depletion/dizziness plus zolpidem-related sedation and impaired balance is a plausible additive risk, not a documented one for this specific pair
- Direct trial or case evidence on this combination / not identified in the sources reviewed for this page; verification against primary literature and interaction databases is advised before making a strong claim
- Populations warranting extra caution / adults over 65, patients on loop or thiazide diuretics, patients with significant hepatic or renal impairment
- Dose adjustment / no pharmacokinetic-based dose change is described in either drug's FDA label for this combination
How these two drugs relate to each other
Dapagliflozin is the generic name for the brand-name drug Farxiga, an SGLT2 (sodium-glucose cotransporter-2) inhibitor. It is FDA-approved for type 2 diabetes, heart failure, and chronic kidney disease, and works by increasing urinary glucose and sodium excretion. Zolpidem, sold as Ambien among other brand names, is a non-benzodiazepine GABA-A receptor agonist ("Z-drug") approved for short-term treatment of insomnia and controlled as a Schedule IV substance.
People treated for type 2 diabetes, heart failure, or chronic kidney disease frequently also have insomnia, so the two drugs are commonly taken by the same patient. That overlap is a reasonable clinical question even though it does not by itself establish a documented drug-drug interaction.
Dapagliflozin and zolpidem do not share a metabolic pathway, so a pharmacokinetic interaction between them is not expected based on their FDA-approved prescribing information; the more realistic concern is a pharmacodynamic one, where dapagliflozin's volume-depleting, dizziness-associated effects could add to zolpidem's sedative and balance-impairing effects, especially overnight in older adults or people on diuretics. No interaction-specific trial or published case report on this exact pairing was located during this review, so that pharmacodynamic concern should be treated as plausible and mechanism-based rather than as a proven clinical finding.
What the pharmacokinetics actually show
According to the FDA-approved dapagliflozin prescribing information, dapagliflozin is metabolized primarily through UGT1A9-mediated glucuronidation and is not meaningfully metabolized by cytochrome P450 (CYP) enzymes. Its label states that co-administration with CYP inducers or inhibitors is not expected to meaningfully change dapagliflozin exposure (per the FDA-approved dapagliflozin prescribing information).
According to the FDA-approved zolpidem prescribing information, zolpidem is metabolized primarily by CYP3A4, with minor contributions from other CYP enzymes (per the FDA-approved zolpidem prescribing information). Dapagliflozin is not described in its label as a CYP3A4 inhibitor or inducer, which is the pharmacologic basis for expecting no meaningful effect on zolpidem clearance. Neither label describes the other drug as a substrate, inhibitor, or inducer of the enzyme system the other drug depends on.
This absence of a shared pathway is a reasonable basis for saying a pharmacokinetic interaction is unlikely. It is not the same as saying the combination has been specifically studied and found safe together; it means the mechanism for a blood-level interaction is not present in the labeling.
The more realistic concern: additive dizziness and fall risk
The FDA label for dapagliflozin lists dizziness and volume-depletion-related adverse events (including symptomatic hypotension) among its known risks, particularly in patients who are elderly, have low systolic blood pressure, or are on diuretics. The FDA label for zolpidem lists dizziness, impaired coordination, and next-morning sedation among its known risks, and the FDA issued a 2013 safety communication lowering the recommended starting dose for women after data showed a meaningful proportion of women had next-morning blood levels associated with impaired driving (per an FDA drug safety communication issued in 2013).
Neither label describes a specific combined-use warning for the other drug. The pharmacodynamic concern discussed here is a reasonable inference from two separately documented side-effect profiles, not a finding from a trial that tested the combination directly. Large cardiovascular and kidney outcome trials of dapagliflozin have reported dizziness and volume-depletion events as adverse events in their safety data, and diuretic use is a recognized factor that increases that risk; however, this review did not locate a verified source reporting event rates specifically in patients also taking zolpidem, and any specific percentage attributed to that subgroup should be treated as unverified until confirmed against the primary trial publications.
Evidence-status assessment for this interaction
| Status | What it means here | Basis |
|---|---|---|
| Established | Dapagliflozin is cleared mainly through UGT1A9; zolpidem is cleared mainly through CYP3A4. | FDA prescribing information for each drug |
| Established | Both drugs independently list dizziness as a recognized adverse effect; zolpidem separately carries a next-morning impairment warning. | FDA prescribing information; 2013 FDA safety communication |
| Plausible but unproven | Dapagliflozin-related volume depletion could add to zolpidem-related sedation and impair balance, particularly overnight. | Mechanism-based inference from each drug's separate profile; no combination-specific trial identified |
| Not established | Any specific numeric estimate of added fall or dizziness risk when the two drugs are used together. | No case series, cohort study, or trial arm testing this specific pairing was located |
| Verify before relying on it | How individual commercial interaction-checking tools (e.g., the checker used in your pharmacy or EHR) currently classify this pair. | These databases are proprietary, updated on their own schedule, and were not independently queried for this review |
What a clinician or pharmacist should verify before counseling on this combination
- Confirm the patient's current interaction-checker output at the point of prescribing rather than relying on a general summary, since severity flags can change with label updates.
- Confirm whether the patient is also on a loop or thiazide diuretic, since that combination with dapagliflozin has an established volume-depletion signal independent of zolpidem.
- Confirm renal function (eGFR) and recent orthostatic blood pressure, since these affect how much additional pharmacodynamic risk zolpidem sedation adds.
- Confirm the zolpidem dose is consistent with current FDA-recommended starting doses (lower dose in women, and in older adults) rather than assuming it was set correctly at an earlier visit.
- If a fall, near-fall, or significant dizziness episode is reported after starting both drugs, evaluate volume status and medication timing before assuming either drug alone is responsible.
Practical steps that reduce the plausible risk
Taking dapagliflozin in the morning shifts its diuretic effect to daytime hours, which can reduce nighttime urination (nocturia) and therefore reduce the number of times a sedated patient needs to get out of bed overnight. This is a reasonable, low-risk practice, though it is a general clinical recommendation rather than a rule specific to zolpidem co-administration.
Basic fall-prevention steps are appropriate for anyone combining a sedative-hypnotic with a drug that can cause volume depletion: rising slowly from bed, keeping a clear and lit path to the bathroom, and avoiding alcohol, since alcohol independently worsens zolpidem-related sedation and impairs judgment about fluid intake. Adults over 65, and anyone on additional diuretics or with reduced kidney or liver function, warrant closer monitoring of blood pressure, renal function, and morning alertness after either drug is started or the dose is changed.
What this page does not establish
This review did not locate a dedicated clinical trial, cohort study, or published case report evaluating dapagliflozin and zolpidem taken together. The pharmacodynamic concern described above is a mechanism-based, clinically reasonable inference from each drug's independently documented side-effect profile, not a demonstrated finding about the combination itself. Statements about how specific commercial drug-interaction databases classify this pair, and any precise adverse-event percentages attributed to combined use, should be verified directly against those databases and against the primary trial publications before being presented to a patient as an established fact.
This information is educational and does not replace individualized medical advice. Anyone experiencing significant dizziness, a fall, fainting, or unusual confusion after starting either medication should contact their prescriber, and anyone with signs of severe dehydration, chest pain, or loss of consciousness should seek urgent care.